Skip to main content
ONCODESIGN logo

ONCODESIGN — Investor Relations & Filings

Ticker · ALONC ISIN · FR0011766229 LEI · 9695004HPDBVG72O8851 PA Professional, scientific and technical activities
Open in API
Filings indexed 237 across all filing types
Latest filing 2022-12-13 Delisting Announcement
Country FR France
Listing PA ALONC

About ONCODESIGN

https://www.oncodesign.com/

Oncodesign Precision Medicine is a biotechnology company specializing in precision medicine. Its mission is to develop and deliver innovative therapeutic and diagnostic solutions to treat resistant and metastatic cancers. The company utilizes a unique, patient-centric model and a proprietary technology platform to discover and advance effective treatments. This approach is centered on translational thinking, aiming to address the challenges of therapeutic resistance and metastasis evolution by focusing on unmet patient needs.

Recent filings

Filing Released Lang Actions
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
Delisting Announcement Classification · 1% confidence The document is a formal press release dated December 13, 2022, titled 'COMMUNIQUE RELATIF À LA MISE EN OEUVRE DU RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIÉTÉ' (Communiqué regarding the implementation of the mandatory squeeze-out targeting the company's shares). It explicitly references compliance with French AMF (Autorité des marchés financiers) regulations (Article 237-3 III of the General Regulation) concerning mandatory buyouts following a simplified public tender offer (OPA simplifiée). The content details the final steps, compensation amount (€14.42 per share), and the effective date (December 22, 2022) for delisting shares not acquired during the preceding tender offer. This process is directly related to the conclusion of a takeover/merger activity and the subsequent mandatory share cancellation/buyout. While it relates to the outcome of a takeover (TAR), the core subject is the mandatory acquisition/delisting process following the successful tender offer, which often falls under M&A activity documentation or, given the specific nature of mandatory buyouts and delisting, could be considered a specialized regulatory filing. Since the document announces the final step of a takeover process (the mandatory squeeze-out leading to delisting), the most fitting category is 'M&A Activity' (TAR), as it is the direct consequence of the preceding takeover bid. It is not a general regulatory filing (RNS) because it is highly specific to a M&A event outcome.
2022-12-13 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds under French commercial law. It details that Cancer Buster Bidco crossed the 90% threshold of capital and voting rights in ONCODESIGN. This type of filing specifically reports changes in significant share ownership levels by an entity or individual, often crossing regulatory thresholds. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure, not a general announcement (RPA/RNS) or a full annual/interim report.
2022-12-13 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition de la note d'information visée ou de la note en réponse visée
M&A Activity Classification · 1% confidence The document is a 'COMMUNIQUE' dated November 24, 2022, relating to the availability of an information note ('NOTE D'INFORMATION') concerning a Simplified Public Tender Offer ('OFFRE PUBLIQUE D'ACHAT SIMPLIFIÉE') initiated by Cancer Buster Bidco SAS for the shares of Oncodesign. It explicitly mentions the AMF (Autorité des marchés financiers) visa and compliance with specific articles of the AMF General Regulation (e.g., 231-27, 231-28). This document is an announcement regarding the regulatory filing (the Information Note) related to a takeover bid/merger activity. Since the core subject is a Tender Offer (Offre Publique d'Achat), the most appropriate category is M&A Activity (TAR). Although it is an announcement, the subject matter is specific enough to override the general RPA/RNS fallback, as TAR specifically covers merger proposals or takeover bids.
2022-11-24 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition de la note d'information visée ou de la note en réponse visée
M&A Activity Classification · 1% confidence The document is titled "OFFRE PUBLIQUE D'ACHAT SIMPLIFIÉE" (Simplified Public Purchase Offer) and explicitly mentions being a "Note d'information" (Information Memorandum) established by Cancer Buster Bidco SAS, which has received visa n°22-458 from the AMF (Autorité des marchés financiers). This document details the terms, price, duration, and legal framework of a takeover bid for Oncodesign shares. This structure and content strongly align with regulatory filings related to tender offers or takeovers, which fall under the category of M&A Activity (TAR) in this classification scheme, as it is a formal document detailing a takeover proposal.
2022-11-23 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition de la note d'information visée ou de la note en réponse visée
M&A Activity Classification · 1% confidence The document is titled "NOTE EN REPONSE RELATIVE A L'OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE" (Response Note relating to the Simplified Public Purchase Offer targeting the company's shares). It explicitly mentions the Autorité des marchés financiers (AMF) visa, the offer price, the duration of the offer, and details the terms of a takeover bid (Offre Publique d'Achat Simplifiée). This content is characteristic of documents filed during a tender offer or takeover process. Since the document is a detailed response note concerning a takeover bid, it falls under the category of M&A Activity (TAR). It is not a general regulatory filing (RNS) because it is highly specific to a takeover, nor is it a general report like a 10-K or IR.
2022-11-23 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition du projet de note d'information ou du projet de note en réponse
M&A Activity Classification · 1% confidence The document is titled "PROJET DE NOTE EN REPONSE RELATIVE A L'OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE" (Draft Response Document concerning the Simplified Public Purchase Offer targeting the company's shares). It explicitly mentions being filed with the 'Autorité des marchés financiers (l'AMF)' and references specific articles of the AMF general regulation (e.g., 231-13, 231-16, 231-18). This document is the target company's formal response to a takeover bid initiated by another entity. This type of filing, related to a tender offer (Offre Publique d'Achat - OPA), is a specific regulatory disclosure concerning M&A activity. Among the provided codes, 'TAR' (M&A Activity) is the most appropriate classification for documents detailing the terms, context, and response to a takeover bid or merger proposal.
2022-11-08 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.